quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:15:00·15d
PRRelease
Annovis Bio Inc. logo
Arcutis Biotherapeutics Inc. logo
Intellia Therapeutics Inc. logo
+1

The Credibility Filter Wall Street Uses to Sort Biotech Winners

ANVS· Annovis Bio Inc.ARQT· Arcutis Biotherapeutics Inc.NTLA· Intellia Therapeutics Inc.STOK· Stoke Therapeutics Inc.
Health Care
Original source

Companies

  • ANVS
    Annovis Bio Inc.
    Health Care
  • ARQT
    Arcutis Biotherapeutics Inc.
    Health Care
  • NTLA
    Intellia Therapeutics Inc.
    Health Care
  • STOK
    Stoke Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 2NTLAUpdateWilliam Blair-
  • Feb 24STOKUpdateWolfe Research$40.00
  • Feb 5STOKUpdateGuggenheim$60.00
  • Jan 5STOKUpdateChardan Capital Markets$35.00
  • Nov 12NTLAUpdateWolfe Research-
  • Nov 11NTLAUpdateEvercore ISI$8.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Stoke Therapeutics Inc.
  • SEC1d
    SEC Form DEF 14A filed by Stoke Therapeutics Inc.
  • PR1d
    Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
  • SEC2d
    SEC Form S-8 filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEFA14A filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Arcutis Biotherapeutics Inc.
  • PR7d
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  • PR8d
    Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022